FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment

Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling review for its NDA and selected COMP360 for the Commissioner’s National Priority Voucher/CNPV program. COMP360 is a proprietary synthetic psilocybin formulation designed for patients with treatment-resistant depression/TRD.

The CNPV designation provides the company with enhanced regulatory communication and a significantly shortened review timeline of one to two months once the application is filed, though the drug must still meet all standard FDA requirements for safety and efficacy. The decision is supported by positive data from two large Phase 3 clinical trials involving over 1,000 participants. These trials demonstrated that COMP360 could produce clinically meaningful effects as quickly as one day after administration, with results lasting at least six months for many patients.

FDA Grants Rolling Review and CNPV Designation to Compass Pathways (CMPS) for TRD Treatment

25 Best Online Psychology Degree Programs Heading Into 2024

The safety profile indicated that most adverse events were mild to moderate and typically resolved within 24 hours. The CEO emphasized that this regulatory progress validates the urgent need for innovation in the mental health field, particularly for the estimated 4 million people in the US living with TRD. As the most advanced company in the field of classic psychedelics, Compass Pathways (NASDAQ:CMPS) is currently preparing for the commercial launch of COMP360.

Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues. Its flagship drug candidate COMP360 is being developed as a solution for treatment-resistant depression as well as post-traumatic stress disorder.

While we acknowledge the risk and potential of CMPS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.